🇺🇸 FDA
Pipeline program

Dexlansoprazole

TAK-390MR_204

Phase 2 small_molecule active

Quick answer

Dexlansoprazole for Gastroesophageal Reflux Disease (GERD) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Gastroesophageal Reflux Disease (GERD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials